First Clinical Trial Using Stem Cell Therapy To Treat Septic Shock

Research using the production of mesenchymal stem cells (MSCs) is expanding—leading to clinically relevant discoveries across therapeutic areas. Led by Dr. David Courtman, Director Biotherapeutics, the Ottawa Hospital Research Institute’s Cell Manufacturing Facility successfully conducted a Phase I clinical trial examining the safety and efficacy of allogeneic bone marrow-derived MSCs as a treatment for patients experiencing septic shock.

In their Phase I trial, freshly cultured allogeneic bone marrow-derived MSCs were dosed into patients with septic shock.¹ A single dose was manufactured using the Corning® HYPERFlask® on an as-needed basis. Since dosing was developed on an emergent per-patient basis, researchers were notified of a patient enrollment and had to deliver the dose within 6 hours.